Literature DB >> 10435018

Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts.

U Kirchhefer1, W Schmitz, H Scholz, J Neumann.   

Abstract

OBJECTIVES: A hallmark of human heart failure is prolonged myocardial relaxation. Although the intrinsic mechanism of phospholamban coupling to the Ca(2+)-ATPase is unaltered in normal and failed human hearts, it remains possible that regulation of phospholamban phosphorylation by cAMP-dependent mechanisms or other second messenger pathways could be perturbed, which may account partially for the observed dysfunctions of the sarcoplasmic reticulum (SR) associated with this disease.
METHODS: cAMP-dependent protein kinase (PKA) and Ca2+/calmodulin-dependent protein kinase II (CaM kinase) were characterized initially by DEAE-Sepharose chromatography in hearts from patients with end-stage dilated cardiomyopathy. We measured the activity of PKA and CaM kinase in left ventricular tissue of failing (idiopathic dilated cardiomyopathy; ischemic heart disease) and nonfailing human hearts.
RESULTS: Basal PKA activity was not changed between failing and nonfailing hearts. One major peak of CaM kinase activity was detected by DEAE-Sepharose chromatography. CaM kinase activity was increased almost 3-fold in idiopathic dilated cardiomyopathy. In addition, hemodynamical data (left ventricular ejection fraction, cardiac index) from patients suffering from IDC positively correlate with CaM kinase activity.
CONCLUSIONS: Increased CaM kinase activity in hearts from patients with dilated cardiomyopathy could play a role in the abnormal Ca2+ handling of the SR and heart muscle cell.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435018     DOI: 10.1016/s0008-6363(98)00296-x

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  90 in total

Review 1.  Transcriptional regulation by cAMP in the heart.

Authors:  F U Müller; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 2.  Is CaMKII a link between inflammation and hypertrophy in heart?

Authors:  Madhu V Singh; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2011-01-29       Impact factor: 4.599

Review 3.  CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction.

Authors:  Chad E Grueter; Roger J Colbran; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2006-11-21       Impact factor: 4.599

4.  SR-targeted CaMKII inhibition improves SR Ca²+ handling, but accelerates cardiac remodeling in mice overexpressing CaMKIIδC.

Authors:  Sabine Huke; Jaime Desantiago; Marcia A Kaetzel; Shikha Mishra; Joan H Brown; John R Dedman; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2010-10-21       Impact factor: 5.000

5.  CaMKII-induced shift in modal gating explains L-type Ca(2+) current facilitation: a modeling study.

Authors:  Yasmin L Hashambhoy; Raimond L Winslow; Joseph L Greenstein
Journal:  Biophys J       Date:  2009-03-04       Impact factor: 4.033

6.  Calmodulin/CaMKII inhibition improves intercellular communication and impulse propagation in the heart and is antiarrhythmic under conditions when fibrosis is absent.

Authors:  Hiroki Takanari; Vincent J A Bourgonje; Magda S C Fontes; Antonia J A Raaijmakers; Helen Driessen; John A Jansen; Roel van der Nagel; Bart Kok; Leonie van Stuijvenberg; Mohamed Boulaksil; Yoshio Takemoto; Masatoshi Yamazaki; Yukiomi Tsuji; Haruo Honjo; Kaichiro Kamiya; Itsuo Kodama; Mark E Anderson; Marcel A G van der Heyden; Harold V M van Rijen; Toon A B van Veen; Marc A Vos
Journal:  Cardiovasc Res       Date:  2016-06-29       Impact factor: 10.787

7.  Posttranslational modifications of calcium/calmodulin-dependent protein kinase IIδ and its downstream signaling in human failing hearts.

Authors:  Tomas Rajtik; Eva Goncalvesova; Zoltan V Varga; Przemyslaw Leszek; Mariusz Kusmierczyk; Michal Hulman; Jan Kyselovic; Peter Ferdinandy; Adriana Adameova
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 8.  New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII).

Authors:  Adam G Rokita; Mark E Anderson
Journal:  Circulation       Date:  2012-10-23       Impact factor: 29.690

9.  Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice.

Authors:  Tong Zhang; Tao Guo; Shikha Mishra; Nancy D Dalton; Evangelia G Kranias; Kirk L Peterson; Donald M Bers; Joan Heller Brown
Journal:  Circ Res       Date:  2009-12-03       Impact factor: 17.367

10.  Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.

Authors:  Chun Li Zhang; Timothy A McKinsey; Shurong Chang; Christopher L Antos; Joseph A Hill; Eric N Olson
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.